Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

San Francisco’s Audentes Therapeutics Inks Deal to Buy Cardiogen Sciences

San Francisco-based Audentes Therapeutics, announced today that it will buy Cardiogen Sciences, Inc., headquartered in Palo Alto, Calif. Financial details were not disclosed.   Audentes focuses on developing and commercializing adeno-associated virus (AAV) gene therapies for rare diseases. It currently has three products in development, AT001 for X-Linked Myotubular Myopathy (XLMTM), AT002 for Pompe disease, […]

Read More »

Bristol-Myers buys rights to acquire fibrosis drug developer

Drugmaker Bristol-Myers Squibb said it bought rights to a mid-stage fibrosis drug and its privately held developer for up to $1.25 billion, boosting its pipeline for drugs that treat tissue scarring. The deal gives Bristol-Myers access to Promedior Inc’s lead experimental drug, PRM-151, which is being tested to treat two types of fibrosis. PRM-151 is […]

Read More »

Amicus Snaps up Scioderm and its Lead EB Drug in Deal Worth $847 Million

CRANBURY, N.J. – Amicus Therapeutics, Inc. (FOLD) inked a deal to acquire the privately-held biopharmaceutical company Scioderm Inc., Inc. in a deal worth up to $847 million, the company announced this morning.   The acquisition places Scioderm’s lead product candidate Zorblisa, a topical cream for the treatment of Epidermolysis Bullosa (EB) into Amicus’ rare and […]

Read More »

A Day After Investing $1.7 Billion in North Carolina, Novo Nordisk A/S Buys Two Indiana Biotech Companies

Novo Nordisk (NVO), headquartered in Copenhagen, Denmark, announced yesterday that it will buy Calibrium LLC and MB2 LLC, two private biopharma companies based in Indiana.   Calibrium, located in Carmel, Ind., focuses on developing drug candidates for diabetes and related metabolic diseases. It was co-founded by Fritz French, the company’s chief executive officer, and Richard […]

Read More »

FTC May Require Products Worth $600 Million to be Divested for Teva-Allergan Deal to Go Through

MUMBAI: As Israeli drugmaker Teva readies to acquire Allergan as part of its recent $40.5-billion deal, a large bounty of products is expected to be up for grabs for generic drugmakers. According to collated data, products worth nearly $600 million may be needed to be divested as part of the anti-trust regulations of the US […]

Read More »

Sucampo Offers to Buy R-Tech Ueno for $278 Million

Sucampo Launches Tender Offer to Acquire R-Tech Ueno Acquisition Expected to be Immediately Accretive Advances Sucampo Strategy to Strengthen Financial Performance and Diversify Pipeline Acquisition Expected to Close in Q4 2015 Company to Host Conference Call Today at 8:00 a.m. EDT   BETHESDA, Md., Aug. 26, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) today […]

Read More »

Medtronic Jumps Into Mitral Valve Race with $458 Million Deal for Twelve Inc.

Medtronic To Acquire Twelve, Developer Of Transcatheter Mitral Valve Replacement Device DUBLIN – August 25, 2015 – In support of the company’s therapy innovation strategy, Medtronic plc (NYSE: MDT) today announced that it has signed a definitive agreement to acquire Twelve, Inc. (“Twelve”), a privately-held medical device company based in Redwood City, Calif., focused on […]

Read More »

BD to Acquire Cellular Research to Develop a Leading Genomics Platform for Single Cell Analysis

FRANKLIN LAKES, N.J., Aug. 25, 2015 /PRNewswire/ — BD Life Sciences, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), today announced it has completed the acquisition of Cellular Research, Inc. BD is a global leader in characterizing and isolating single cells for analysis, with more than 30 years […]

Read More »

China’s Hepalink USA to Buy American Firm Cytovance for $205.68M+

Hepalink USA, the wholly owned U.S. subsidiary of Shenzhen Hepalink Pharmaceutical, will acquire the biopharmaceutical contract development manufacturing organization Cytovance® Biologics for $205.68 million cash plus additional contingent payments, Cytovance said today. The deal adds a CDMO to Hepalink’s U.S. portfolio, which includes Scientific Protein Laboratories (SPL), a global supplier of active pharmaceutical ingredients (APIs). […]

Read More »

Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin

Talazoparib Is a Highly-Potent PARP Inhibitor in Phase 3 Development for the Treatment of BRCA-Mutated Breast Cancer; Clinical Activity Observed in Multiple Oncology Opportunities With Potential for Monotherapy or Combination Therapy With Standard of Care Oncology Treatments; Transaction Price of $410 Million Upfront, Up to $160 Million in Milestones and Mid-Single Digit Royalties SAN FRANCISCO, […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom